Fig. 17
From: First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
OS(C-A) derived from the model simulation
Fig. 17 | Orphanet Journal of Rare Diseases
From: First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
OS(C-A) derived from the model simulation
Orphanet Journal of Rare Diseases